Literature DB >> 9207212

Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells.

M Shinoda1, K Toide, I Ohsawa, S Kohsaka.   

Abstract

A potent and specific prolyl endopeptidase inhibitor, JTP-4819, was used to investigate the role of prolyl endopeptidase in the generation of amyloid beta protein (A beta) from APP by NG108-15 cells. Synthetic substrates, 7-(succinyl-Ile-Ala)-4-methylcoumarinamide and Z(Val-Lys-Met)-4-methylcoumarinamide, respectively, corresponding to the C-terminal and N-terminal portions of A beta, were cleaved by NG108-15 cell lysates. Cleavage of the C-terminal portion, but not the N-terminal, was inhibited by JTP-4819 (IC50 = 0.6 nM). Western blot analysis showed that the A beta level in the culture medium of NG108-15 cells was increased by serum deprivation. JTP-4819 caused concentration (>10(-9) M)- and time-dependent inhibition of this serum deprivation-induced increase of A beta without having any effect on the level of the secretory form of APP. Using both specific anti-A beta (1-40) and anti-A beta (1-42) antisera, the A beta that increased with serum deprivation was confirmed to be A beta (1-40), suggesting that it might be produced by conversion of A beta (1-42) to A beta (1-40). These findings indicate that prolyl endopeptidase may be a key enzyme in the production of A beta by NG108-15 cells and that A beta secretion can be modulated by a prolyl endopeptidase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207212     DOI: 10.1006/bbrc.1997.6730

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Novel proline endopeptidase inhibitors do not modify Abeta40/42 formation and degradation by human cells expressing wild-type and swedish mutated beta-amyloid precursor protein.

Authors:  A Petit; H Barelli; P Morain; F Checler
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases.

Authors:  Caitlin M Daimon; Patrick Chirdon; Stuart Maudsley; Bronwen Martin
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013

Review 3.  Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.

Authors:  Timo T Myöhänen; J Arturo García-Horsman; Jofre Tenorio-Laranga; Pekka T Männistö
Journal:  J Histochem Cytochem       Date:  2009-05-26       Impact factor: 2.479

4.  Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.

Authors:  Jarkko I Venäläinen; Risto O Juvonen; J Arturo Garcia-Horsman; Erik A A Wallén; Johannes A M Christiaans; Elina M Jarho; Jukka Gynther; Pekka T Männistö
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

5.  Structural analysis of prolyl oligopeptidases using molecular docking and dynamics: insights into conformational changes and ligand binding.

Authors:  Swati Kaushik; Ramanathan Sowdhamini
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

6.  Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?

Authors:  Pekka T Männistö; J Arturo García-Horsman
Journal:  Front Aging Neurosci       Date:  2017-02-14       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.